NASDAQ · VSTM
Healthcare · Biotechnology
$10.10
Down-$0.27 (-2.62%)
Updated Oct 28, 2026, 10:58 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VSTM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 27, 2026
VSTM closed at $10.10 after 21 trading sessions, up 27.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 27, 2026 | $9.945 | $10.15 | $9.76 | $10.10 | 4.71M |
| Oct 26, 2026 | $10.00 | $10.1625 | $9.3416 | $10.00 | 4.29M |
| Oct 23, 2026 | $10.085 | $10.22 | $9.71 | $10.04 | 3.76M |
| Oct 22, 2026 | $9.20 | $10.11 | $9.14 | $10.06 | 5.95M |
| Oct 21, 2026 | $9.41 | $9.67 | $9.12 | $9.21 | 3.06M |
| Oct 20, 2026 | $8.62 | $9.4701 | $8.57 | $9.34 | 3.96M |
| Oct 19, 2026 | $8.58 | $9.17 | $8.51 | $8.62 | 3.4M |
| Oct 16, 2026 | $9.235 | $9.37 | $8.53 | $8.65 | 6.09M |
| Oct 15, 2026 | $8.04 | $9.73 | $7.77 | $9.23 | 16.96M |
| Oct 14, 2026 | $8.00 | $8.955 | $6.70 | $7.71 | 33.76M |
| Oct 13, 2026 | $8.15 | $8.20 | $7.445 | $7.45 | 3.43M |
| Oct 12, 2026 | $8.42 | $8.60 | $8.075 | $8.25 | 3.58M |
| Oct 9, 2026 | $8.12 | $8.58 | $7.98 | $8.38 | 2.97M |
| Oct 8, 2026 | $8.20 | $8.28 | $7.72 | $8.11 | 3.05M |
| Oct 7, 2026 | $7.77 | $8.355 | $7.65 | $8.265 | 3.93M |
| Oct 6, 2026 | $8.08 | $8.18 | $7.695 | $7.75 | 2.51M |
| Oct 5, 2026 | $7.74 | $8.10 | $7.52 | $8.00 | 2.22M |
| Oct 2, 2026 | $7.95 | $8.015 | $7.52 | $7.70 | 4.07M |
| Oct 1, 2026 | $8.00 | $8.175 | $7.74 | $7.90 | 1.76M |
| Sep 30, 2026 | $7.98 | $8.40 | $7.92 | $8.05 | 1.57M |
| Sep 29, 2026 | $7.78 | $8.12 | $7.56 | $7.92 | 2.68M |
The latest Smart Investors Daily articles mentioning VSTM.
Company
Market Activity
Research & News
VSTM research
Company profile and research snapshot.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | BTIG | Buy | — |
| Oct 16, 2026 | Mizuho | Outperform | — |
| Oct 15, 2026 | RBC Capital | Outperform | — |
| Oct 15, 2026 | Jefferies | Buy | — |
| Oct 15, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Oct 20, 2026
Incyte Corporation shares ESMO 2026 highlights: KRAS G12D, INCA33890 and CDK2 combos show solid tumor promise ahead of Jakafi LOEâclick for more on INCY stock.
Benzinga · Oct 19, 2026
BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $24 price target.
Benzinga · Oct 16, 2026
Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $13 to $14.
Yahoo · Oct 16, 2026
Verastem (VSTM) is in focus after releasing detailed TARGET-D 101 trial data for VS-7375 in KRAS G12D-mutated tumors and then quickly following up with a roughly US$250 million follow-on equity raise. The TARGET-D 101 update and the roughly US$250 million equity raise arrived on top of an already strong run, with Verastem’s 1-day share price return of 19.71% and 90-day share price return of 53.07% pointing to accelerating momentum. At the same time, the 1-year total shareholder return is...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VSTM.
